Drugs / GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2
last change Apr 2009 re-read 3 minutes ago

GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2

Vaccine

Developed for
tuberculosis
Investigated by
GlaxoSmithKline

Trials 1

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00621322 Apr 2008 → Apr 2009 tuberculosis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00621322 ↗
Modality Vaccine “692342 tuberculosis vaccine” NCT00621322 ↗
Route Intramuscular “Intramuscular injection, 2 doses” NCT00621322 ↗